UBS Group Issues Positive Forecast for Kodiak Sciences (NASDAQ:KOD) Stock Price

Kodiak Sciences (NASDAQ:KOD) had its price objective raised by UBS Group from $50.00 to $80.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

KOD has been the subject of several other research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and set a $58.00 target price (up from $38.00) on shares of Kodiak Sciences in a report on Friday. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $35.43.

Kodiak Sciences Stock Performance

NASDAQ KOD opened at $37.00 on Friday. Kodiak Sciences has a one year low of $1.92 and a one year high of $45.60. The company’s 50 day moving average price is $25.14 and its 200 day moving average price is $21.81. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of -8.98 and a beta of 2.61.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KOD. AQR Capital Management LLC bought a new stake in shares of Kodiak Sciences in the 1st quarter worth about $188,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Kodiak Sciences during the first quarter worth about $94,000. Jane Street Group LLC lifted its position in shares of Kodiak Sciences by 441.3% during the first quarter. Jane Street Group LLC now owns 64,649 shares of the company’s stock worth $181,000 after purchasing an additional 52,705 shares during the last quarter. American Century Companies Inc. grew its stake in Kodiak Sciences by 6.3% in the second quarter. American Century Companies Inc. now owns 79,745 shares of the company’s stock worth $297,000 after purchasing an additional 4,703 shares in the last quarter. Finally, Panagora Asset Management Inc. increased its holdings in Kodiak Sciences by 28.5% in the second quarter. Panagora Asset Management Inc. now owns 131,122 shares of the company’s stock valued at $489,000 after buying an additional 29,113 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

Key Stories Impacting Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Topline Phase 3 (GLOW2) win for Zenkuda: Kodiak reported that Zenkuda (tarcocimab tedromer) met the primary endpoint in GLOW2, showing a large improvement in diabetic retinopathy severity (62.5% of treated patients achieved ≥2‑step DRSS improvement vs 3.3% for sham) with a 6‑month dosing interval — a result that materially raises the drug’s efficacy and commercial prospects. PR Newswire
• Positive Sentiment: Market reaction: The GLOW2 news triggered large intraday rallies (reports of 50–75%+ moves) as traders repriced KOD for a potential regulatory filing and eventual launch. This surge reflected investor expectations that the program can support a Biologics License Application (BLA) and a valuable ophthalmology franchise. Reuters
• Positive Sentiment: Analyst upgrades and higher price targets: Following the data, UBS raised its price target to $80 with a Buy rating and HC Wainwright reaffirmed Buy while raising its target to $58 — both moves signal increased sell‑side conviction and provide further upside narrative for investors. Benzinga (UBS) TickerReport (HC Wainwright)
• Neutral Sentiment: Regulatory path and next steps: Coverage notes and industry press indicate a likely BLA filing is now the logical next step; timing and FDA interactions remain catalysts but are not guaranteed. Positive data increase probability, but approval and commercial uptake timelines still carry execution risk. BioWorld
• Negative Sentiment: Volatility and hedging activity: There was unusually high put option activity the day of the results (large put volumes vs typical), indicating some traders were hedging or positioning for downside — a sign of elevated speculative interest and potential for sharp intraday reversals. (Options flow reported 3,472 puts vs typical ~256.)
• Negative Sentiment: Today’s pullback amid heavy volume: After the strong rally on the data, the shares have pulled back today on very heavy trading — a common post‑news profit taking and volatility washout that increases short‑term risk despite the fundamentally positive trial news.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.